Skip to content


You currently have no items in your basket.


AtaGenix Laboratories, located in Wuhan, China, was established in 2012. The company evolved from ProteoGenix; a leading therapeutic antibody development service provider based in France. With a staff comprised of highly trained professionals from both countries, AtaGenix offers a wide range of catalogue products and custom services to meet a diversity of research requirements. 2BScientific customers regularly turn to us for AtaGenix’ antibody and protein reagents. We notice a lot of interest in the company’s primary antibodies against various small molecules, as well as in AtaGenix’ selection of human recombinant interleukin proteins, cytokines, and growth factors.

View All AtaGenix Products
  • 100% guaranteed

As the main part of the modern biomedical industry, antibody drugs account for about 50% of global biopharmaceutical market. Antibody biosimilars are emerging biopharmaceutic market. Since the best-selling patents for several antibody drugs have expired, this provide an opportunity for antibody-drug analogues.

Antibody-drug analogues and biological original drugs contain similar active substances, which are similar in quality, safety and effectiveness, there is no difference in clinical significance. On November 7, 2019, the first adalimumab biosimilar drug BAT1406 was approved for marketing in China, which accelerated the development of antibody drugs. AtaGenix is now launching antibody-drug analogues to support the development of antibody drugs.

We use cookies to give you the best experience of using this website. By continuing to use this site, you accept our use of cookies. Please read our Cookie Policy for more information.